左心室アシスト装置の移植後の右心不全管理におけるヴェリシガットの使用: 症例報告
Tasuku Hada1, Takuya Watanabe1, Satsuki Fukushima2
1From the Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
まとめ
左心室補助器 (LVAD) を使った患者の右心不全 (RHF) を改善した. この発見は,RHFのLVAD移植後の潜在的な治療法として, vericiguatを示唆しています.
科学分野:
- 心臓病科
- 薬理学について
背景:
- 右心不全 (RHF) は,左心室補助器 (LVAD) を使っている患者の死亡の重要な原因です.
- LVAD後のRHFの現在の治療戦略は限られています.
- 溶解性ガニラートサイクラゼ刺激剤であるヴェリシグアートは,心不全の治療において有望であることが示されています.
研究 の 目的:
- 左心室補助装置 (LVAD) を使っている患者の右心不全 (RHF) の管理における vericiguatの有効性を評価する.
主な方法:
- 進行性心不全の62歳の女性患者の症例報告
- 肺高血圧を評価するために右心経導管検査.
- 術後のRHFに対する従来の治療法 (イノトロプ,肺血管拡張剤) の失敗後の投与.
主要な成果:
- ベリシグアトの投与により,心臓の出力量が増加し,RHFの症状が改善されました.
- 静脈間隔壁の位置の最適化が観察されました.
- 患者の状態は, vericiguatを加えた後改善しました.
結論:
- ベリシグアットは,LVAD患者における右心不全の管理のための新しい治療法である可能性があります.
- この患者集団における vericiguatの役割を確認するために,さらなる研究が必要である.
関連する概念動画
Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
Mitral Regurgitation III: Medical Management
30
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
30
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Aortic Regurgitation III: Medical Management
42
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
42


